Evropska unija - nemščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Evropska unija - nemščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Švica - nemščina - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - filmtabletten - erlotinibum 25 mg ut erlotinibi hydrochloridum, lactosum monohydricum 23.98 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.2 mg. - onkologikum - synthetika

Švica - nemščina - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - filmtabletten - erlotinibum 100 mg ut erlotinibi hydrochloridum, lactosum monohydricum 95.93 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.7 mg. - onkologikum - synthetika

Švica - nemščina - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - filmtabletten - erlotinibum 150 mg ut erlotinibi hydrochloridum, lactosum monohydricum 143.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 1.1 mg. - onkologikum - synthetika

Belgija - nemščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - erlotinib-hydrochlorid - filmtablette - 25 mg - erlotinib-hydrochlorid 27.32 mg - erlotinib

Belgija - nemščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - erlotinib-hydrochlorid - filmtablette - 50 mg - erlotinib-hydrochlorid 54.63 mg - erlotinib

Belgija - nemščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - erlotinib-hydrochlorid - filmtablette - 100 mg - erlotinib-hydrochlorid 109.27 mg - erlotinib

Belgija - nemščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - erlotinib-hydrochlorid - filmtablette - 150 mg - erlotinib-hydrochlorid 163.9 mg - erlotinib

Belgija - nemščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - erlotinib-hydrochlorid - filmtablette - 25 mg - erlotinib-hydrochlorid 27.32 mg - erlotinib